Intelligence · Clinical Pipeline
Phase III Pipeline Programs
Late-stage pivotal and registrational clinical programs nearing regulatory submission.
- Programs
- 5,427
Quick answer
NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.
Top sponsors
- Takeda 393 programs
- United Therapeutics Europe 199 programs
- Anaxis Pharma 198 programs
- Chinese Academy of 189 programs
- Teva Pharma 148 programs
- Novartis India 145 programs
- BRIGHT MINDS BIOSCIENCES 139 programs
- PARItec 139 programs
- HOFFMANN-LA ROCHE 134 programs
- Regeneron UK 129 programs
- AstraZeneca 120 programs
- First People's Hospital 117 programs
-
CALCIUM FOLINATE, IRINOTECAN HYDROCHLORIDE TRIHYDRATE, BEVACIZUMAB, BEVACIZUMAB, PANITUMUMAB, SOTORASIB, FLUOROURACIL
Amgen
Colorectal Cancer (CRC)
1 trial -
CALCIUM FOLINATE, OPDIVO 10 mg/mL concentrate for solution for infusion., BNT327 20 mg ml, OXALIPLATIN, FLUOROURACIL, BNT327 50 mg ml, CAPECITABINE, CAPECITABINE
Bristol-Myers Squibb Australia Pty Ltd
Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
1 trial -
CAM2029 (octreotide subcutaneous depot), CAM2029 (octreotide subcutaneous depot)
Camurus Pty Ltd
Acromegaly
1 trial -
CAM2029 (octreotide subcutaneous depot), SANDOSTATIN LAR 30 mg powder and solvent for suspension for injection, Somatuline Autogel 120 mg, solution for injection in a pre-filled syringe
Camurus Pty Ltd
gastroenteropancreatic neuroendocrine tumors
1 trial -
CANAKINUMAB, PEMETREXED
Novartis Pharmaceuticals
Non-small cell lung cancer
1 trial -
CAPECITABINE
Disc Medicine
Salivary Duct Carcinoma
1 trial -
CAPECITABINE , METFORMIN , ACETYLSALICYLIC ACID , OXALIPLATIN
Fondazione Telethon ETS
Locally advanced stage II/III rectal cancer
1 trial -
CAPECITABINE, CAPECITABINE, CARBOPLATIN, Datopotamab deruxtecan, ERIBULIN MESYLATE, PACLITAXEL ALBUMIN-BOUND, PACLITAXEL
AstraZeneca AB
Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer
1 trial -
CAPECITABINE, DS-8201a, INFLIXIMAB, CISPLATIN, MYCOPHENOLATE MOFETIL, CAPECITABINE, KEYTRUDA 25 mg/mL concentrate for solution for infusion, FLUOROURACIL, Rilvegostomig, OXALIPLATIN, TRASTUZUMAB
AstraZeneca AB
HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
1 trial -
CAPECITABINE, Fluorouracil 50 mg/ml Solution for Injection or Infusion, Oxaliplatin 5mg/ml concentrate for solution for infusion, CETUXIMAB, ENCORAFENIB, Calcium Folinate 10 mg/ml Injection, CAMPTO 20 mg/mL concentrate for solution for infusion, Irinotecan hydrochloride 20 mg/ml concentrate for solution for infusion, CAMPTO 20 mg/mL concentrate for solution for infusion, FLUOROURACIL, IRINOTECAN, Bevacizumab, CALCIUM FOLINATE, Capecitabine, Cetuximab, OXALIPLATIN, Oxaliplatin 5mg/ml concentrate for Solution
Pfizer Australia Pty Ltd
Colorectal cancer (BRAF V600E-mutant mCRC)
1 trial -
CAPECITABINE, PACLITAXEL, CAPECITABINE, DS-8201a, Abraxane 5 mg/ml powder for dispersion for infusion.
AstraZeneca AB
HER2-Low, Hormone Receptor Positive Breast Cancer which has Progressed on Endocrine Therapy in the Metastatic Setting.
1 trial -
CARBOPLATIN , -, -, PARACETAMOL , CIMETIDINE , DOCETAXEL , PACLITAXEL , MK-2870, KEYTRUDA 25 mg/mL concentrate for solution for infusion, -
Merck Sharp and Dohme
pMMR endometrial carcinoma
1 trial -
CARBOPLATIN , FLUOROURACIL , JNJ-61186372, CISPLATIN , PEMBROLIZUMAB
Janssen-Cilag International N.V.
Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
1 trial -
CARBOPLATIN, CARBOPLATIN, DS-8201a, PEMETREXED, CISPLATIN, PEMBROLIZUMAB
Daiichi Sankyo
Unresectable or Metastatic HER2 overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer
1 trial -
CARBOPLATIN, CARBOPLATIN, IPILIMUMAB, PEMETREXED, CISPLATIN, INFLIXIMAB, PEMETREXED, Mycofit, 250 mg, kapsułki twarde, NIVOLUMAB, volrustomig
AstraZeneca AB
Unresectable Pleural Mesothelioma
1 trial -
CARBOPLATIN, CARBOPLATIN, Patritumab deruxtecan, PEMETREXED, CISPLATIN
Daiichi Sankyo
Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC)
1 trial -
CARBOPLATIN, CISPLATIN, PEGFILGRASTIM, PEMETREXED, BL-B01D1
Bristol-Myers Squibb Australia Pty Ltd
EGFR-mutated Non-small Cell Lung Cancer
1 trial -
CARBOPLATIN, CISPLATIN, PEMBROLIZUMAB, PEMETREXED, DS-8201a, PEMETREXED
AstraZeneca AB
Unresectable, locally advanced, or metastatic Non-Small Cell Lung Cancer with HER2 exon 19 or 20 mutations
1 trial -
CARBOPLATIN, CISPLATIN, PEMETREXED, CARBOPLATIN, PEMETREXED, OSIMERTINIB, CISPLATIN, Telisotuzumab adizutecan, OSIMERTINIB, CARBOPLATIN, PEMETREXED
AbbVie Deutschland GmbH & Co. KG
Non-Squamous Non-Small Cell Lung Cancer
1 trial -
CARBOPLATIN, GEMCITABINE, PEMBROLIZUMAB, CISPLATIN, BT8009, AVELUMAB
BICYCLE THERAPEUTICS
Locally advanced or metastatic urothelial cancer
1 trial -
CARBOPLATIN, GEMCITABINE, PEMETREXED, Sindaxel 6 mg/ml concentrat pentru soluţie perfuzabilă, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CISPLATIN, Abraxane 5 mg/ml powder for dispersion for infusion., RO 749-9790/F02-02
Hoffmann-La Roche
RET fusion−positive, metastatic Non-Small Cell Lung Cancer
1 trial -
CARBOPLATIN, PACLITAXEL, DOCETAXEL, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion
Merck Sharp and Dohme
Endometrial cancer
1 trial -
CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride
Sarepta Therapeutics
Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.
1 trial -
CAZ-AVI
Pfizer
Complicated Intra-Abdominal Infection
1 trial -
CBD 100 mg/mL Oral Solution
COGNITION THERAPEUTICS INC
Psychosis
1 trial -
CBD 100 mg/mL Oral Solution
COGNITION THERAPEUTICS INC
Treatment Resistant Psychosis
1 trial -
CBP-201
S.L
Atopic Dermatitis
2 trials -
CDZ173/Leniolisib, CDZ173/Leniolisib
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
CDZ173/Leniolisib, CDZ173/Leniolisib, CDZ173/Leniolisib
Pharming Technologies B.V.
Activated Phosphoinositide 3-Kinase Delta Syndrome
1 trial -
CEFTAZIDIME, PIPERACILLIN, CEFTAZIDIME AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE, CEFTAZIDIME, CEFEPIME , CEFEPIME, MEROPENEM , TAZOBACTAM, TAZOBACTAM, MEROPENEM, AMIKACIN , AMIKACIN, PIPERACILLIN AND BETA-LACTAMASE INHIBITOR , CEFTOLOZANE AND BETA-LACTAMASE INHIBITOR , AVIBACTAM, CEFTAZIDIME
Pari Pharma GmbH
antibiotic therapy in Sepsis
1 trial -
CEFTRIAXONE , CEFIXIME , SULFAMETHOXAZOLE AND TRIMETHOPRIM , AMIKACIN
Pari Pharma GmbH
acute pyelonephritis (AP) in children
1 trial -
CEFTRIAXONE , TEMOCILLIN , Negaban 2 g poudre pour solution injectable/pour perfusion
Pari Pharma GmbH
Neisseria gonorrhoeae Infections
1 trial -
CEFTRIAXONE VIATRIS 1 g, poudre pour solution injectable, Clarithromycine EG 500 mg comprimés pelliculés, MÉTRONIDAZOLE ARROW 500 mg, comprimé pelliculé sécable
Pari Pharma GmbH
Pregnant women with singleton pregnancies hospitalized for threatened late miscarriage with intact membranes
1 trial -
CEFTRIAXONE, AMOXICILLIN, AZITHROMYCIN
Pari Pharma GmbH
Population of study participants Pregnant women with PPROM at 22 to 33 weeks’ gestation
1 trial -
CELLULOSE, MICROCRYSTALLINE, OSELTAMIVIR , DEXAMETHASONE
The George Institute
Severe Influenza
1 trial -
CEP-10953 (Armodafinil)
Teva Pharma GmbH
Narcolepsy
1 trial -
CEP-1347 10mg
Teva Pharma GmbH
Parkinson Disease
1 trial -
CEP-33457
Teva Pharma GmbH
Systemic Lupus Erythematosus
2 trials -
CETUXIMAB
Disc Medicine
oral squamous cell carcinoma
1 trial -
CF101
Can-Fite BioPharma
Keratoconjunctivitis Sicca
2 trials -
CF101
Can-Fite BioPharma
Plaque Psoriasis
1 trial -
CF101 1 mg
Can-Fite BioPharma
Rheumatoid Arthritis
1 trial -
CF101 2mg
Can-Fite BioPharma
Plaque Psoriasis
1 trial -
CG0070 Adenovirus Vector
CG Oncology
Transitional Cell Carcinoma
1 trial -
CGT9486 plus sunitinib
Cogent Biosciences
Advanced Gastrointestinal Stromal Tumors
1 trial -
CHAMPIX 0.5 mg film-coated tablets, Placebo CHAMPIX ® 0.5mg Comprimé pelliculé
Pari Pharma GmbH
Smokers smoking at least 10 cigarettes/day in the past year
1 trial -
CHF 5993 100/6/12.5 µg
Chiesi Farmaceutici S.p.A.
COPD (Chronic Obstructive Pulmonary Disease)
1 trial -
CHF6001 DPI, CHF6001 DPI, Placebo to match CHF6001 DPI
Chiesi Farmaceutici S.p.A
Chronic obstructive pulmonary disease (COPD) and Chronic Bronchitis
1 trial
Frequently asked questions
How many Phase III pipeline programs are in the directory?
5,427 published programs match this development stage in our ClinicalTrials.gov index.
What defines this pipeline stage?
Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.
Data attribution: Data sources · All pipeline programs